Soluble Thrombomodulin Levels in 51 HFRS Patients

Clinical data from 51 patients with Hemorrhagic Fever with Renal Syndrome (HFRS) treated between January 2023 and January 2024. It focuses on soluble thrombomodulin (sTM) levels, correlating them with disease phases, severity subtypes, SOFA scores, and 28-day mortality outcomes.

Use Cases

• Analyze the correlation between sTM levels and SOFA scores (R²=0.6076) for severity assessment in HFRS patients.
• Evaluate the predictive value of sTM for 28-day mortality risk using the provided cut-off value of 49.98 TU/mL.
• Compare sTM level distributions across HFRS disease phases (febrile, hypotensive, oliguria-dipuria) and severity subtypes (mild, moderate, severe, critical).
• Assess the combined predictive ability of sTM and SOFA scores, which achieved an AUC of 0.9492 for mortality risk.

Strengths

• Data includes 51 HFRS patient records with detailed clinical measurements.
• Strong statistical correlations are reported, such as R²=0.6076 between sTM and SOFA scores.
• Provides a specific sTM cut-off value (49.98 TU/mL) with 81.36% sensitivity and 100% specificity for mortality prediction.

Limitations

• Small sample size of 51 patients limits statistical power and generalizability.
• Data is from a single hospital's Infectious Diseases Department, potentially introducing geographic or institutional bias.
• Retrospective study design may have inherent limitations in data completeness and control.

Provenance

Source

Infectious Diseases Department of the Second Affiliated Hospital of Air Force Medical University.

Collection Method

Retrospective analysis of patient medical records.

Time Range

January 2023 to January 2024.

Freshness

Data covers patients treated up to January 2024, with the record last updated in March 2026.

Geography

Hospital location not specified, presumed to be in China based on author and institution names.